未知生产厂商
Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine is a vaccine comprising purified SARS-CoV-2 spike protein expressed in plant-based virus-like particles for the prevention of COVID-19 in adult patients.
Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine is a vaccine comprising purified SARS-CoV-2 spike protein expressed in plant-based virus-like particles for the prevention of COVID-19 in adult patients.
Covifenz is a recombinant and adjuvanted vaccine produced by plant-based technology. The antigenic portion of the vaccine is produced by delivering the SARS-CoV-2 spike protein genomic sequence into host leaf cells of non-transgenic plants utilizing a bacterial vector. The newly transgenic plant then serves as a bioreactor for producing virus-like particles (VLPs), which are self-assembled structures that resemble viruses but are absent viral genetic material and therefore non-infectious. The enveloped VLPs present spike protein trimers stabilized in a pre-fusion conformation on their surface which, following intramuscular administration, elicit both neutralizing antibody and cellular immune responses to SARS-CoV-2 spike proteins. Covifenz also contains an adjuvant, AS03, which is mixed with the antigenic component prior to administration to enhance the immune response to the vaccine.
The Covifenz COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in patients 18 years of age and older.
共 1 项相关疾病
